Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/13/2025 | $153.00 | Outperform → Market Perform | Leerink Partners |
| 12/10/2024 | $166.00 | Neutral | BofA Securities |
| 11/15/2024 | $190.00 | Outperform | Wolfe Research |
| 7/23/2024 | $160.00 → $150.00 | Outperform → Neutral | Daiwa Securities |
| 5/30/2024 | $160.00 | Neutral | Goldman |
| 4/18/2024 | $170.00 | Hold → Buy | HSBC Securities |
| 12/13/2023 | $170.00 → $163.00 | Overweight → Equal Weight | Wells Fargo |
| 12/1/2023 | $167.00 → $180.00 | Neutral → Buy | UBS |
Jury concludes J&J concealed the danger of its asbestos-laced talcum powder that caused woman's cancer A Suffolk County jury has awarded $8 million in favor of Janice Paluzzi, a Massachusetts woman who developed mesothelioma after decades of using Johnson & Johnson's (NYSE:JNJ) talcum powder products. The jury found the pharmaceutical giant liable for negligence and breach of warranty, concluding that the company's asbestos-contaminated talcum powder products caused Paluzzi's terminal cancer. During the trial, the Dean Omar Branham Shirley legal team, which represented Ms. Paluzzi, presented extensive evidence showing that Johnson & Johnson had internal knowledge of asbestos in its ta
Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease 75-80% complete response rate among evaluable patients at the recommended Phase 2 dose MILAN, June 13, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous chimeric antigen receptor (CAR) T-cell therapy, being studied in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have not been previously treated with CAR T-cell therapy.1 Findin
TREMFYA ® demonstrated two and a half times greater ability to inhibit joint structural damage versus placebo in the Phase 3b APEX study More than 40% of TREMFYA®-treated patients across both dose groups achieved ACR50 at Week 24 Improvement in both joint and skin symptoms reinforce TREMFYA® as a first-line treatment option with a proven safety profile for adults with active psoriatic arthritis BARCELONA, June 11, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced findings from the Phase 3b APEX study showing that TREMFYA® (guselkumab) significantly reduced both signs and symptoms of active psoriatic arthritis (PsA) and inhibited progression of joint structural damage at 24 w
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)